by Gemma Escarré,
Enantia, CataloniaBio & HealthTech member, has again succeeded in applying cocrystallisation technology to a new family of compounds, the cannabinoids.
Cannabinoids, especially cannabidiol (CBD) and tetrahydrocannabinol (THC), plays an important role in a number of biochemical pathways. Besides Sativex® and Epidiolex®, the only two approved drugs containing CBD, the potential of cannabinoids to be used to treat a large number of medical conditions is very high as is shown by the number of ongoing clinical trials.
Enantia has developed new cannabinoid cocrystals to allow their purification from complex mixtures (natural and synthetic) and to obtain improved active pharmaceutical ingredients and drug formulations.
Enantia is open to discuss with possible partners the licensing of this technology for different uses. Expressions of interest can be directed to Joan Feixas, Enantia's CEO.
The company, created in 2003 at the Barcelona Science Park (PCB), is specialised in R&D Process Chemistry, Solid Form Development, and Medicinal Chemistry.